Release Date:  February 2, 2022
Expiration Date:  February 1, 2023

Activity Overview
Watch the experts who are actively engaged in the care of patients with relapsed/refractory multiple myeloma as they reinforce key points and highlight the most clinically relevant data presented at the ASH 2021 Annual Meeting. 

Target Audience
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with multiple myeloma.

Learning Objectives
After participating in this activity, participants should be better able to:

• Incorporate minimal residual disease assessment when evaluating prognosis and potential relapse
• Evaluate treatment approaches for patients with relapsed and/or refractory MM, specifically the decision to include a monoclonal bispecific antibody, or antibody-drug conjugate, CAR T cell therapy, and combination with other agents for triplet therapy
• Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with RR MM
• Discuss the results of clinical trials that are investigating emerging novel agents in patients with RR MM

Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend.  University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must:

1) read the educational objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Faculty Disclosures
All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Faculty
Sagar Lonial, MD, FACP
Chief Medical Officer
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Faculty and Planning Committee Disclosures
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Faculty
Sagar Lonial, MD, FACP
Consulting Fees: Amgen Inc., Bristol-Myers Squibb Company, Bluebird, Celgene Corporation, Genentech, Novartis, Sanofi, Takeda Oncology
Other: Board of Directors TG Therapeutics with stock

Krina Patel, MD, MSc
Consulting Fees: Bristol Myers Squibb Company, Janssen, Pfizer, Arcellx

Planning Committee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Jennifer Bechan; Chloe Dunnam, Dru Dace, PhD; Kraig Steubing

Support
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Sanofi Genzyme, Oncopeptides, and Legend Biotech.

Technical Requirements
This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.